Description

Combating Pseudomonas aeruginosa infections with antimicrobial peptide carriers

The bacterium Pseudomonas aeruginosa is a leading cause of hospital-acquired infections, including ventilator-associated pneumonia and sepsis. This pathogen exacerbates the condition of already compromised patients and exhibits high resistance to antibiotics, posing a significant challenge in healthcare settings. Our innovative project aims to combat P. aeruginosa through a novel approach involving carriers for antimicrobial peptides (AMPs).

The primary objective is to ensure the effective delivery of potent AMPs directly into the bacterial cells, thereby maximizing their antimicrobial activity. By encapsulating AMPs within specialized carriers, we strive to create a targeted therapeutic system capable of eradicating P. aeruginosa infections.

In the final phase of the project, the AMP-loaded carriers will be administered via an aerosol delivery system, enabling efficient targeting of bacterial infections in the lungs. To validate our approach and assess its efficacy, we will initially test the system using a less harmful strain, such as Pseudomonas fluorescens, as a model organism.

This cutting-edge research holds promise for developing effective treatments against P. aeruginosa infections, potentially improving patient outcomes and reducing the burden on healthcare systems.